Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | MPL | P40238 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4058013 | 0.81 | CYP1A2 (0.56) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL20047604 | 0.79 | CYP1A2 (0.46) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL13737910 | 0.74 | CYP1A2 (0.48) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL4052149 | 0.74 | CYP1A2 (0.48) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL13739182 | 0.74 | CYP1A2 (0.48) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL5342120 | 0.74 | MPL (0.33) | MPLCYP11B1CYP11B2 | |
| SCHEMBL10259445 | 0.73 | CYP1A2 (0.68) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL7243856 | 0.72 | PDE10A (0.34) | PTPN1MPLCYP11B1CYP11B2 | |
| SCHEMBL22754 | 0.72 | CYP1A2 (0.55) | PTPN1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL13737717 | 0.71 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | PTPN1 1940/4885CYP1A2 681/4885KDM4E 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.